Renata Limited, one of Bangladesh’s leading pharmaceutical companies, has officially commenced the export of rivaroxaban capsules to Australia, marking a significant milestone in the company’s global expansion and regulatory achievements.

Rivaroxaban is an oral anticoagulant used to prevent and treat blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of stroke in patients with atrial fibrillation. The medicine is widely prescribed worldwide and is part of the World Health Organization’s list of essential medicines.

Renata’s entry into the highly regulated Australian pharmaceutical market underscores the company’s strong manufacturing capabilities and its compliance with stringent international quality standards. This achievement follows the successful approval of its rivaroxaban capsules by the Therapeutic Goods Administration (TGA) of Australia.

A senior official at Renata commented, “This is a proud moment for Renata and for the pharmaceutical industry of Bangladesh. Exporting to Australia proves that Bangladeshi manufacturers can meet global regulatory and quality benchmarks. It also opens the door to other regulated markets.”

This development not only enhances Renata’s presence in the Asia-Pacific region but also contributes to Bangladesh’s growing reputation as a reliable source of high-quality, affordable generic medicines.

With exports already reaching over 30 countries, Renata’s entry into the Australian market is expected to further boost the country’s pharmaceutical export earnings and showcase its potential as a global pharmaceutical hub.